Neumora Therapeutics, Inc. Common Stock
NMRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $142 | $374 | $241 | $409 |
| Short-Term Investments | $165 | $80 | $131 | $0 |
| Receivables | $0 | $1 | $1 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $6 | $23 | $15 | $6 |
| Total Curr. Assets | $314 | $478 | $388 | $416 |
| Property Plant & Equip (Net) | $3 | $7 | $11 | $4 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $10 | $24 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $1 | $4 | $10 |
| Total NC Assets | $3 | $18 | $38 | $14 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $317 | $496 | $426 | $429 |
| Liabilities | – | – | – | – |
| Payables | $3 | $0 | $7 | $2 |
| Short-Term Debt | $2 | $3 | $3 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $25 | $21 | $13 | $21 |
| Total Curr. Liab. | $30 | $25 | $24 | $23 |
| LT Debt | $0 | $2 | $5 | $1 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $844 | $730 |
| Total NC Liab. | $0 | $2 | $849 | $731 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $2 | $5 | $8 | $2 |
| Total Liabilities | $30 | $27 | $873 | $755 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$947 | -$703 | -$468 | -$337 |
| AOCI | $0 | -$0 | -$1 | $0 |
| Other Equity | $1,234 | $1,173 | $21 | $11 |
| Total Equity | $287 | $469 | -$447 | -$325 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $317 | $496 | $426 | $429 |
| Net Debt | -$140 | -$369 | -$233 | -$407 |